1 |
Análise imuno-histoquímica do transportador de glicose-1 em hiperplasia fibrosa inflamatória e carcinoma epidermóide oral. / Imunohistochemical analysis of glucose transporter-1 in hyperplaia fibrous inflamatory and oral squamous cell carcinoma.Ponte, José Sérgio January 2013 (has links)
PONTE, J.S. Análise imuno-histoquímica do transportador de glicose-1 em hiperplasia fibrosa inflamatória e carcinoma epidermóide oral. 2013. 77 f. Dissertação. (MESTRADO EM BIOTECNOLOGIA) - Campus de Sobral, Universidade Federal do Ceará, Sobral, 2013. / Submitted by Djeanne Costa (djeannecosta@gmail.com) on 2017-08-23T13:33:56Z
No. of bitstreams: 1
2013_dis_jsponte.pdf: 1853429 bytes, checksum: c2551c1c3d35636d7fc7eb9f4366f186 (MD5) / Approved for entry into archive by Djeanne Costa (djeannecosta@gmail.com) on 2017-09-27T12:08:02Z (GMT) No. of bitstreams: 1
2013_dis_jsponte.pdf: 1853429 bytes, checksum: c2551c1c3d35636d7fc7eb9f4366f186 (MD5) / Made available in DSpace on 2017-09-27T12:08:02Z (GMT). No. of bitstreams: 1
2013_dis_jsponte.pdf: 1853429 bytes, checksum: c2551c1c3d35636d7fc7eb9f4366f186 (MD5)
Previous issue date: 2013 / Cancer is still a big target of scientific studies and research, to be an important cause of morbidity and mortality worldwide. Oral squamous cell carcinoma (CEO) is the most prevalent form of cancer in the mouth, and despite the great advances and discoveries, the prognosis of this cancer is still poor, mainly discovered in advanced stages. Oral carcinogenesis is a complex and multiple genes can be altered in this process. Several proteins are altered in these tumors, highlighting more recently, proteins of cellular metabolism, especially glucose transporters (GLUT). The objective of this research was to evaluate the immunohistochemical expression of GLUT-1 in comparison with CEO inflammatory fibrous hyperplasia (HFI), a non-neoplastic proliferative lesion. The sample consisted of 30 cases of oral lesions, 15 cases of HFI CEO and 15. We used immunohistochemical technique Estreptoavitina-Biotin with GLUT-1 antibody (Genetex, dilution 1:300, 60 minutes, antigen retrieval with citrate pH 6), analyzing 05 fields in each case 100X, telling the percentage of positive cells. As a result it was found that the mean percentage of epithelial cells positive for GLUT-1 in inflammatory fibrous hyperplasia group was 85.6 ± 0.9% (median = 85.6% = 81.0% minimum, maximum = 90.1%). The mean percentage of epithelial cells positive for GLUT-1 in the group of squamous cell carcinoma was 89.6 ± 2.7% (median = 92.2% = 72.2% minimum, maximum = 98.0%). Could observe a statistically significant difference between the two study groups (p = 0.033, Mann-Whitney test). The percentage of immune cells marked as to the location where the CEO shows a higher percentage of 93.4% in the alveolar ridge compared to the tongue (64.7%). Based on the results of this research, it was observed that there is an increased expression of GLUT-1 in lesions in carcinomas than in hyperplastic, and this may probably reflect the involvement of GLUT in some oncogenic mechanism. However, more studies are needed to further elucidate the involvement of this protein in oral carcinogenesis. / O câncer continua sendo grande alvo de estudos e investigações científicas, por ser importante causa de morbidade e mortalidade em todo mundo. O carcinoma epidermoide oral (CEO) é a forma mais prevalente de câncer em boca, e apesar dos grandes avanços e descobertas, o prognóstico desse tipo de câncer ainda é pobre, principalmente se descoberto em estágios avançados. A carcinogênese oral é um processo complexo e vários genes podem estar alterados neste processo. Várias proteínas estão alteradas nesses tumores, destacando-se mais recentemente, as proteínas do metabolismo celular, especialmente os Transportadores de Glicose (GLUT). O objetivo da presente pesquisa foi avaliar a expressão imuno-histoquímica de GLUT-1 em CEO comparando com Hiperplasia Fibrosa Inflamatória (HFI), uma lesão proliferativa não-neoplásica. A amostra foi constituída por 30 casos de lesões orais, sendo 15 casos de CEO e 15 HFI. Utilizou-se a técnica imuno-histoquímica da Estreptoavitina-Biotina com o anticorpo GLUT-1 (marca Genetex, diluição 1:300, 60 minutos, recuperação antigênica com citrato pH6), analisando 05 campos de cada caso no aumento de 100X, contando-se o percentual de células positivas. Como resultado obteve-se que a média do percentual de células epiteliais positivas para GLUT-1 no grupo de HFI foi 85.6±0.9% (mediana = 85.6%, mínima = 81.0%, máxima = 90.1%). A média do percentual de células epiteliais positivas para GLUT-1 no grupo de CEO foi 89.6±2.7% (mediana = 92.2%, mínima = 72.2%, máxima = 98.0%). Pôde-se observar diferença estatisticamente significante entre os dois grupos de estudo (p=0.033, teste Mann-Whitney). O percentual de células imunomarcadas quanto à localização nos casos de CEO mostra um percentual maior de 93,4% no rebordo alveolar quando comparado com a língua (64.7%). Com base nos resultados desta pesquisa, observou-se que há uma maior expressão da GLUT-1 nas lesões nos carcinomas do que nas hiperplasias, e isso, pode provavelmente refletir a participação da GLUT em algum mecanismo oncogênico. Contudo, mais estudos são necessários para elucidar melhor a participação desta proteína na carcinogênese oral.
|
2 |
AnÃlise imuno-histoquÃmica do transportador de glicose-1 em hiperplasia fibrosa inflamatÃria e carcinoma epidermÃide oral / Imunohistochemical analysis of glucose transporter-1 in hyperplaia fibrous inflamatory and oral squamous cell carcinoma.Josà SÃrgio Ponte 18 December 2013 (has links)
FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgico / Cancer is still a big target of scientific studies and research, to be an important cause of morbidity and mortality worldwide. Oral squamous cell carcinoma (CEO) is the most prevalent form of cancer in the mouth, and despite the great advances and discoveries, the prognosis of this cancer is still poor, mainly discovered in advanced stages. Oral carcinogenesis is a complex and multiple genes can be altered in this process. Several proteins are altered in these tumors, highlighting more recently, proteins of cellular metabolism, especially glucose transporters (GLUT). The objective of this research was to evaluate the immunohistochemical expression of GLUT-1 in comparison with CEO inflammatory fibrous hyperplasia (HFI), a non-neoplastic proliferative lesion. The sample consisted of 30 cases of oral lesions, 15 cases of HFI CEO and 15. We used immunohistochemical technique Estreptoavitina-Biotin with GLUT-1 antibody (Genetex, dilution 1:300, 60 minutes, antigen retrieval with citrate pH 6), analyzing 05 fields in each case 100X, telling the percentage of positive cells. As a result it was found that the mean percentage of epithelial cells positive for GLUT-1 in inflammatory fibrous hyperplasia group was 85.6  0.9% (median = 85.6% = 81.0% minimum, maximum = 90.1%). The mean percentage of epithelial cells positive for GLUT-1 in the group of squamous cell carcinoma was 89.6  2.7% (median = 92.2% = 72.2% minimum, maximum = 98.0%). Could observe a statistically significant difference between the two study groups (p = 0.033, Mann-Whitney test). The percentage of immune cells marked as to the location where the CEO shows a higher percentage of 93.4% in the alveolar ridge compared to the tongue (64.7%). Based on the results of this research, it was observed that there is an increased expression of GLUT-1 in lesions in carcinomas than in hyperplastic, and this may probably reflect the involvement of GLUT in some oncogenic mechanism. However, more studies are needed to further elucidate the involvement of this protein in oral carcinogenesis. / O cÃncer continua sendo grande alvo de estudos e investigaÃÃes cientÃficas, por ser importante causa de morbidade e mortalidade em todo mundo. O carcinoma epidermoide oral (CEO) à a forma mais prevalente de cÃncer em boca, e apesar dos grandes avanÃos e descobertas, o prognÃstico desse tipo de cÃncer ainda à pobre, principalmente se descoberto em estÃgios avanÃados. A carcinogÃnese oral à um processo complexo e vÃrios genes podem estar alterados neste processo. VÃrias proteÃnas estÃo alteradas nesses tumores, destacando-se mais recentemente, as proteÃnas do metabolismo celular, especialmente os Transportadores de Glicose (GLUT). O objetivo da presente pesquisa foi avaliar a expressÃo imuno-histoquÃmica de GLUT-1 em CEO comparando com Hiperplasia Fibrosa InflamatÃria (HFI), uma lesÃo proliferativa nÃo-neoplÃsica. A amostra foi constituÃda por 30 casos de lesÃes orais, sendo 15 casos de CEO e 15 HFI. Utilizou-se a tÃcnica imuno-histoquÃmica da Estreptoavitina-Biotina com o anticorpo GLUT-1 (marca Genetex, diluiÃÃo 1:300, 60 minutos, recuperaÃÃo antigÃnica com citrato pH6), analisando 05 campos de cada caso no aumento de 100X, contando-se o percentual de cÃlulas positivas. Como resultado obteve-se que a mÃdia do percentual de cÃlulas epiteliais positivas para GLUT-1 no grupo de HFI foi 85.6Â0.9% (mediana = 85.6%, mÃnima = 81.0%, mÃxima = 90.1%). A mÃdia do percentual de cÃlulas epiteliais positivas para GLUT-1 no grupo de CEO foi 89.6Â2.7% (mediana = 92.2%, mÃnima = 72.2%, mÃxima = 98.0%). PÃde-se observar diferenÃa estatisticamente significante entre os dois grupos de estudo (p=0.033, teste Mann-Whitney). O percentual de cÃlulas imunomarcadas quanto à localizaÃÃo nos casos de CEO mostra um percentual maior de 93,4% no rebordo alveolar quando comparado com a lÃngua (64.7%). Com base nos resultados desta pesquisa, observou-se que hà uma maior expressÃo da GLUT-1 nas lesÃes nos carcinomas do que nas hiperplasias, e isso, pode provavelmente refletir a participaÃÃo da GLUT em algum mecanismo oncogÃnico. Contudo, mais estudos sÃo necessÃrios para elucidar melhor a participaÃÃo desta proteÃna na carcinogÃnese oral.
|
3 |
Explorative studies to understand if aldehyde dehydrogenase (ALDH) expression in colon cancer can be exploited as a target for therapeutic intervention. Expression profiling of ALDH7A1 in colorectal cancerMagaji, Abdullahi D. January 2022 (has links)
Petroleum Technology Development Fund (PTDF) Nigeria / The full text will be available at the end of the embargo period: 21st March 2026
|
4 |
Alterações em genes relacionados à via glicolítica em tumores de carcinoma epidermoide de esôfago / Alterations in genes involved in glycolysis in esophageal squamous cell carcinomaEster de Andrade Barreto 07 March 2013 (has links)
Conselho Nacional de Desenvolvimento Científico e Tecnológico / O carcinoma epidermoide de esôfago (CEE) representa 90% dos casos de câncer de esôfago no Brasil. O CEE tem detecção tardia, um comportamento extremamente agressivo e baixa sobrevida, sendo, portanto, um alvo interessante para o estudo dos mecanismos envolvidos em sua carcinogênese, a fim de se identificar possíveis alvos terapêuticos ou marcadores moleculares que ajudem na prática clínica. Mudanças no metabolismo energético da célula tumoral parecem ter papel de destaque na transformação maligna. Sabe-se que células tumorais consomem glicose avidamente produzindo ácido lático, mesmo em condições de normóxia. Dentre os fatores que podem contribuir para o estímulo da glicólise em células tumorais destacam-se as alterações em enzimas da via glicolítica tais como: as piruvato-cinases M1 e M2 (PKM1 e PKM2), a hexocinase II (HKII), isofoma 1 do transportador de glicose, GLUT-1, e o fator de transcrição induzido por hipóxia (HIF1α), responsável pela transcrição das proteínas citadas. O objetivo do estudo é avaliar a relação entre a expressão de HIF1α, HK2, PKM2, PKM1 e GLUT-1 e dados clínico-patológicos no CEE. Para tal, foram avaliados tumores conservados em parafina de 44 pacientes com CEE matriculados no INCA e no Hospital das Clínicas de Porto Alegre. Além disso, foram coletadas amostras de biópsia de esôfago em 67 pacientes sem doença esofágica, que foram submetidos à endoscopia no Hospital Universitário Pedro Ernesto (HUPE). A expressão das proteínas foi avaliada nos tecidos por imuno-histoquímica, enquanto que a expressão do mRNA de GLUT-1 também foi avaliada nas amostras controle. Foi observado que as amostras controle expressam HK2, PKM1, PKM2, HIF1α nas camadas do epitélio esofágico. Já GLUT-1 e Ki-67 são vistos apenas na camada basal. Além disso, a expressão do mRNA de GLUT-1 não teve correlação com fatores etiológicos da doença. Em CEE a expressão de HK2, PKM2 e GLUT-1 foi vista em todos os tumores, já a expressão de HIF1α e PKM1 foi variável. Além disso, observou-se que maior expressão de HIF-1α apresenta correlação com invasão linfonodal e diferenciação, enquanto que a expressão de HK2 tem relação com sobrevida e PKM1 com diferenciação. As correlações clínicas encontradas sugerem que alterações no metabolismo energético é um alvo de estudo interessante para desenvolvimento de marcadores moleculares que auxiliem a prática clínica. / The esophageal squamous cell carcinoma (ESCC) represents 90% of cases of esophageal cancer in Brazil. The ESCC has late diagnosis, highly aggressive behavior and poor survival. ESCC is an interesting target to the study of mechanism involved in its carcinogenesis, in order to identify potential drug targets or biomarkers to help clinical practice. Changes in tumor cell energy metabolism appear to have a prominent role in malignant transformation. Tumor cells consume glucose avidly and produce lactic acid, even under normoxia. Among the factors that may contribute to the stimulation of glycolysis in tumor cells, there are changes in the glycolytic pathway enzymes such as: pyruvate kinase M1 and M2 (PKM2 and PKM1), hexokinase II (HKII), glucose transporter isoform 1, GLUT-1, and transcription factor induced by hypoxia (HIF1α), responsible for the transcription of proteins cited. The goal of the study is to evaluate the relationship between the expression of HIF1α, HK2, PKM2, PKM1 and GLUT-1 and clinicopathological data in ESCC. Biopsy of the esophagus in patients without esophageal disease were collected, who underwent endoscopy at University Hospital Pedro Ernesto (HUPE). Tissue samples were collected from 44 patients with a histologically confirmed diagnosis of ESCC recruted from Hospital Universitário Pedro Ernesto (HUPE-UERJ), and Instituto Nacional de Câncer (INCA). Tissue samples from healthy individuals submitted to endoscopic routine examination, not related to cancer or esophageal disorders, at HUPE-UERJ were also included in this study. The expression of proteins in tissues was evaluated by immunohistochemistry, while mRNA expression of GLUT-1 was also evaluated in the control samples. It was observed that the control samples express HK2, PKM1, PKM2, HIF1α layers of the esophageal epithelium. GLUT-1 and Ki-67 are seen only in the basal layer. Furthermore, expression of GLUT-1 mRNA did not correlate with disease etiological factors. In ESCC expression of HK2, PKM2 and GLUT-1 was seen in all tumors, and the expression of HIF1α and PKM1 was variable. We found that increased expression of HIF-1α correlates with lymph node invasion and differentiation, whereas the expression of HK2 is related to survival, and differentiation with PKM1. The clinical correlations found suggest that alterations in energy metabolism are an interesting subject of study for development of biomarkers that help clinical practice.
|
5 |
Einfluss einer autologen Knochenmarkzelltherapie auf reaktive Astrogliose und Glukosetransporter-1-Expression in grauer und weißer Substanz des Großhirns nach fokaler zerebraler Ischämie beim Schafvon Geymüller, Teresa 12 November 2012 (has links) (PDF)
Ziele der hier vorliegenden Arbeit waren eine immunhistochemische Analyse von GFAP (‚glial fibrillary acidic protein’) und GLUT-1 (Glukosetransporter-1) nach fokaler zerebraler Ischämie sowie deren mögliche Beeinflussung durch eine intravenöse Transplantation autologer mononukleärer Knochenmarkzellen (mKMZ) im Schafmodell. Eine differenzierte Analyse der Zielstrukturen in grauer und weißer Substanz (GS bzw. WS) sollte Aufschluss über eventuell unterschiedliche Reaktionsmuster liefern.
Das Gehirnmaterial von zehn Tieren der bereits 2006/2007 stattgefundenen Studie, welche mit PET und MRT-Untersuchungen sowie der Durchführung von Verhaltenstests einherging, wurde retrospektiv im Rahmen der vorliegenden Arbeit untersucht. Je fünf gehörten zu einer Kontroll- bzw. Therapiegruppe (KG bzw. TG). Bei allen Versuchstieren wurde durch die permanente Okklusion der linken mittleren Zerebralarterie (pMCAO) eine fokale zerebrale Ischämie im Bereich des Neokortex hervorgerufen. Die Tiere der Therapiegruppe erhielten 24 Stunden nach dem Eingriff eine Transplantation autologer mKMZ (4x106/kg KGew). Nach sieben Wochen wurden die Versuchstiere getötet, ihre Schädel perfundiert und ihre Gehirne fixiert. Eine Lamelle der Gehirne wurde für die anschließende histologische Untersuchung in 30% Saccharose konserviert.
Nach der Etablierung der Antikörper GFAP und GLUT-1 wurden vier Regionen der Gehirn-lamellen immunhistochemisch markiert und abschließend qualitativ und quantitativ analysiert. Die Regionen I (infarktnah) und III (infarktfern) lagen in der ipsilateralen Hemisphäre, die Regionen II (korrespondierend zu Region I) und IV (korrespondierend zu Region III) in der kontralateralen Hemisphäre. Durch den höheren Substanzverlust an Gehirnmasse in der ipsi-lateralen Hemisphäre der KG, wurden in dieser Tiergruppe die Regionen III und IV nicht ausgewertet. Vor der Analyse sind die physiologischen Markierungsmuster der vier Regionen in grauer und weißer Substanz an zwei gesunden Tieren (Prozesskontrolle) aufgezeigt worden. Durch die elektronenmikroskopische Untersuchung von Präparaten und anhand von GFAP/GLUT-1 doppelmarkierten Präparaten konnte festgestellt werden, dass die Astrozytenendfüßchen durch den hier verwendeten GLUT-1 Antikörper nicht markiert wur-den, sondern dass alleinig die gefäßständige, 55 kDa schwere Isoform detektiert worden ist. Die fokale zerebrale Ischämie führte in beiden Gruppen zu einer hochgradigen reaktiven Astrogliose mit Ausprägung einer Glianarbe in Region I. Protoplasmatische Astrozyten der grauen und fibrilläre Astrozyten der weißen Substanz zeigten hypertrophe Veränderungen. Die reaktive Astrogliose von Region I spiegelte sich in einer erhöhten GFAP-Dichte wider (p<0,05 in der Therapiegruppe). Region III hatte die gleiche GFAP-Dichte wie die Regionen II und IV. Der direkte Vergleich zwischen den Regionen I der beiden Gruppen zeigte Veränderungen der GFAP-Dichte durch die Zelltherapie auf: In der GS der Therapiegruppe lag eine geringere GFAP-Dichte vor, in der WS eine höhere (≠ p<0,05; GS und WS).
Die Ergebnisse der GLUT-1-Analyse sind denen der GFAP-Analyse sehr ähnlich. Durch den Schlaganfall ist es zu einer erhöhten GLUT-1-Expression in GS und WS (p<0,05 WS) von Region I der Kontrollgruppe gekommen. Auch in Region I der Therapiegruppe konnten er-höhte GLUT-1-Dichten in GS und WS (p<0,05 WS) detektiert werden, zusätzlich dazu lag in der GS von Region III der Therapiegruppe eine erhöhte GLUT-1-Dichte vor (p<0,05). Der Vergleich zwischen beiden Gruppen zeigte Veränderungen durch die Therapie für die Regio-nen I und II auf. Die GLUT-1-Dichte der WS war in beiden Regionen in der TG erhöht (p<0,05), die GS von Region I zeigte in der Therapiegruppe eine geringere GLUT-1-Dichte.
Ein Schlaganfall führt zu einer Erhöhung der GFAP sowie GLUT-1-Dichten in WS und GS im infarktnahen Gebiet. Durch die Transplantation von 4x106 autologen mononukleären Knochenmarkzellen pro kg KGew 24 Stunden nach dem Schlaganfall können diese Strukturen in ihren Expressionsmustern beeinflusst werden, dabei reagieren graue und weiße Substanz unterschiedlich: Die GS mit einer Verringerung, die WS mit einer Erhöhung der GFAP- bzw. GLUT-1-Dichte (p<0,05 WS, GLUT-1). Die Funktionskreisläufe in infarktfernen Regionen sind sieben Wochen nach dem Schlaganfall auf Astrozytenebene normalisiert (vgl. Region III). Die erhöhte GLUT-1-Dichte (p<0,05) in der GS der infarktfernen Region ist möglicherweise mit einem erhöhten Glukosemetabolismus in Verbindung zu setzen. Dies kann jedoch erst durch die Auswertung der FDG-PET-Daten beantwortet werden. Ob die durch Transplantation autologer mKMZ festgestellten Veränderungen der GFAP- und GLUT-1-Dichte in der Therapiegruppe zusätzlich mit einer verbesserten motorischen Leistung der Tiere einhergingen, wird erst durch die Analyse der Daten aus den Verhaltenstests festgestellt werden können.
|
6 |
Alterações em genes relacionados à via glicolítica em tumores de carcinoma epidermoide de esôfago / Alterations in genes involved in glycolysis in esophageal squamous cell carcinomaEster de Andrade Barreto 07 March 2013 (has links)
Conselho Nacional de Desenvolvimento Científico e Tecnológico / O carcinoma epidermoide de esôfago (CEE) representa 90% dos casos de câncer de esôfago no Brasil. O CEE tem detecção tardia, um comportamento extremamente agressivo e baixa sobrevida, sendo, portanto, um alvo interessante para o estudo dos mecanismos envolvidos em sua carcinogênese, a fim de se identificar possíveis alvos terapêuticos ou marcadores moleculares que ajudem na prática clínica. Mudanças no metabolismo energético da célula tumoral parecem ter papel de destaque na transformação maligna. Sabe-se que células tumorais consomem glicose avidamente produzindo ácido lático, mesmo em condições de normóxia. Dentre os fatores que podem contribuir para o estímulo da glicólise em células tumorais destacam-se as alterações em enzimas da via glicolítica tais como: as piruvato-cinases M1 e M2 (PKM1 e PKM2), a hexocinase II (HKII), isofoma 1 do transportador de glicose, GLUT-1, e o fator de transcrição induzido por hipóxia (HIF1α), responsável pela transcrição das proteínas citadas. O objetivo do estudo é avaliar a relação entre a expressão de HIF1α, HK2, PKM2, PKM1 e GLUT-1 e dados clínico-patológicos no CEE. Para tal, foram avaliados tumores conservados em parafina de 44 pacientes com CEE matriculados no INCA e no Hospital das Clínicas de Porto Alegre. Além disso, foram coletadas amostras de biópsia de esôfago em 67 pacientes sem doença esofágica, que foram submetidos à endoscopia no Hospital Universitário Pedro Ernesto (HUPE). A expressão das proteínas foi avaliada nos tecidos por imuno-histoquímica, enquanto que a expressão do mRNA de GLUT-1 também foi avaliada nas amostras controle. Foi observado que as amostras controle expressam HK2, PKM1, PKM2, HIF1α nas camadas do epitélio esofágico. Já GLUT-1 e Ki-67 são vistos apenas na camada basal. Além disso, a expressão do mRNA de GLUT-1 não teve correlação com fatores etiológicos da doença. Em CEE a expressão de HK2, PKM2 e GLUT-1 foi vista em todos os tumores, já a expressão de HIF1α e PKM1 foi variável. Além disso, observou-se que maior expressão de HIF-1α apresenta correlação com invasão linfonodal e diferenciação, enquanto que a expressão de HK2 tem relação com sobrevida e PKM1 com diferenciação. As correlações clínicas encontradas sugerem que alterações no metabolismo energético é um alvo de estudo interessante para desenvolvimento de marcadores moleculares que auxiliem a prática clínica. / The esophageal squamous cell carcinoma (ESCC) represents 90% of cases of esophageal cancer in Brazil. The ESCC has late diagnosis, highly aggressive behavior and poor survival. ESCC is an interesting target to the study of mechanism involved in its carcinogenesis, in order to identify potential drug targets or biomarkers to help clinical practice. Changes in tumor cell energy metabolism appear to have a prominent role in malignant transformation. Tumor cells consume glucose avidly and produce lactic acid, even under normoxia. Among the factors that may contribute to the stimulation of glycolysis in tumor cells, there are changes in the glycolytic pathway enzymes such as: pyruvate kinase M1 and M2 (PKM2 and PKM1), hexokinase II (HKII), glucose transporter isoform 1, GLUT-1, and transcription factor induced by hypoxia (HIF1α), responsible for the transcription of proteins cited. The goal of the study is to evaluate the relationship between the expression of HIF1α, HK2, PKM2, PKM1 and GLUT-1 and clinicopathological data in ESCC. Biopsy of the esophagus in patients without esophageal disease were collected, who underwent endoscopy at University Hospital Pedro Ernesto (HUPE). Tissue samples were collected from 44 patients with a histologically confirmed diagnosis of ESCC recruted from Hospital Universitário Pedro Ernesto (HUPE-UERJ), and Instituto Nacional de Câncer (INCA). Tissue samples from healthy individuals submitted to endoscopic routine examination, not related to cancer or esophageal disorders, at HUPE-UERJ were also included in this study. The expression of proteins in tissues was evaluated by immunohistochemistry, while mRNA expression of GLUT-1 was also evaluated in the control samples. It was observed that the control samples express HK2, PKM1, PKM2, HIF1α layers of the esophageal epithelium. GLUT-1 and Ki-67 are seen only in the basal layer. Furthermore, expression of GLUT-1 mRNA did not correlate with disease etiological factors. In ESCC expression of HK2, PKM2 and GLUT-1 was seen in all tumors, and the expression of HIF1α and PKM1 was variable. We found that increased expression of HIF-1α correlates with lymph node invasion and differentiation, whereas the expression of HK2 is related to survival, and differentiation with PKM1. The clinical correlations found suggest that alterations in energy metabolism are an interesting subject of study for development of biomarkers that help clinical practice.
|
7 |
Einfluss einer autologen Knochenmarkzelltherapie auf reaktive Astrogliose und Glukosetransporter-1-Expression in grauer und weißer Substanz des Großhirns nach fokaler zerebraler Ischämie beim Schafvon Geymüller, Teresa 10 July 2012 (has links)
Ziele der hier vorliegenden Arbeit waren eine immunhistochemische Analyse von GFAP (‚glial fibrillary acidic protein’) und GLUT-1 (Glukosetransporter-1) nach fokaler zerebraler Ischämie sowie deren mögliche Beeinflussung durch eine intravenöse Transplantation autologer mononukleärer Knochenmarkzellen (mKMZ) im Schafmodell. Eine differenzierte Analyse der Zielstrukturen in grauer und weißer Substanz (GS bzw. WS) sollte Aufschluss über eventuell unterschiedliche Reaktionsmuster liefern.
Das Gehirnmaterial von zehn Tieren der bereits 2006/2007 stattgefundenen Studie, welche mit PET und MRT-Untersuchungen sowie der Durchführung von Verhaltenstests einherging, wurde retrospektiv im Rahmen der vorliegenden Arbeit untersucht. Je fünf gehörten zu einer Kontroll- bzw. Therapiegruppe (KG bzw. TG). Bei allen Versuchstieren wurde durch die permanente Okklusion der linken mittleren Zerebralarterie (pMCAO) eine fokale zerebrale Ischämie im Bereich des Neokortex hervorgerufen. Die Tiere der Therapiegruppe erhielten 24 Stunden nach dem Eingriff eine Transplantation autologer mKMZ (4x106/kg KGew). Nach sieben Wochen wurden die Versuchstiere getötet, ihre Schädel perfundiert und ihre Gehirne fixiert. Eine Lamelle der Gehirne wurde für die anschließende histologische Untersuchung in 30% Saccharose konserviert.
Nach der Etablierung der Antikörper GFAP und GLUT-1 wurden vier Regionen der Gehirn-lamellen immunhistochemisch markiert und abschließend qualitativ und quantitativ analysiert. Die Regionen I (infarktnah) und III (infarktfern) lagen in der ipsilateralen Hemisphäre, die Regionen II (korrespondierend zu Region I) und IV (korrespondierend zu Region III) in der kontralateralen Hemisphäre. Durch den höheren Substanzverlust an Gehirnmasse in der ipsi-lateralen Hemisphäre der KG, wurden in dieser Tiergruppe die Regionen III und IV nicht ausgewertet. Vor der Analyse sind die physiologischen Markierungsmuster der vier Regionen in grauer und weißer Substanz an zwei gesunden Tieren (Prozesskontrolle) aufgezeigt worden. Durch die elektronenmikroskopische Untersuchung von Präparaten und anhand von GFAP/GLUT-1 doppelmarkierten Präparaten konnte festgestellt werden, dass die Astrozytenendfüßchen durch den hier verwendeten GLUT-1 Antikörper nicht markiert wur-den, sondern dass alleinig die gefäßständige, 55 kDa schwere Isoform detektiert worden ist. Die fokale zerebrale Ischämie führte in beiden Gruppen zu einer hochgradigen reaktiven Astrogliose mit Ausprägung einer Glianarbe in Region I. Protoplasmatische Astrozyten der grauen und fibrilläre Astrozyten der weißen Substanz zeigten hypertrophe Veränderungen. Die reaktive Astrogliose von Region I spiegelte sich in einer erhöhten GFAP-Dichte wider (p<0,05 in der Therapiegruppe). Region III hatte die gleiche GFAP-Dichte wie die Regionen II und IV. Der direkte Vergleich zwischen den Regionen I der beiden Gruppen zeigte Veränderungen der GFAP-Dichte durch die Zelltherapie auf: In der GS der Therapiegruppe lag eine geringere GFAP-Dichte vor, in der WS eine höhere (≠ p<0,05; GS und WS).
Die Ergebnisse der GLUT-1-Analyse sind denen der GFAP-Analyse sehr ähnlich. Durch den Schlaganfall ist es zu einer erhöhten GLUT-1-Expression in GS und WS (p<0,05 WS) von Region I der Kontrollgruppe gekommen. Auch in Region I der Therapiegruppe konnten er-höhte GLUT-1-Dichten in GS und WS (p<0,05 WS) detektiert werden, zusätzlich dazu lag in der GS von Region III der Therapiegruppe eine erhöhte GLUT-1-Dichte vor (p<0,05). Der Vergleich zwischen beiden Gruppen zeigte Veränderungen durch die Therapie für die Regio-nen I und II auf. Die GLUT-1-Dichte der WS war in beiden Regionen in der TG erhöht (p<0,05), die GS von Region I zeigte in der Therapiegruppe eine geringere GLUT-1-Dichte.
Ein Schlaganfall führt zu einer Erhöhung der GFAP sowie GLUT-1-Dichten in WS und GS im infarktnahen Gebiet. Durch die Transplantation von 4x106 autologen mononukleären Knochenmarkzellen pro kg KGew 24 Stunden nach dem Schlaganfall können diese Strukturen in ihren Expressionsmustern beeinflusst werden, dabei reagieren graue und weiße Substanz unterschiedlich: Die GS mit einer Verringerung, die WS mit einer Erhöhung der GFAP- bzw. GLUT-1-Dichte (p<0,05 WS, GLUT-1). Die Funktionskreisläufe in infarktfernen Regionen sind sieben Wochen nach dem Schlaganfall auf Astrozytenebene normalisiert (vgl. Region III). Die erhöhte GLUT-1-Dichte (p<0,05) in der GS der infarktfernen Region ist möglicherweise mit einem erhöhten Glukosemetabolismus in Verbindung zu setzen. Dies kann jedoch erst durch die Auswertung der FDG-PET-Daten beantwortet werden. Ob die durch Transplantation autologer mKMZ festgestellten Veränderungen der GFAP- und GLUT-1-Dichte in der Therapiegruppe zusätzlich mit einer verbesserten motorischen Leistung der Tiere einhergingen, wird erst durch die Analyse der Daten aus den Verhaltenstests festgestellt werden können.
|
8 |
Hypoxia inducible factor-1α in renal cell carcinomaLidgren, Anders January 2007 (has links)
Hypoxia Inducible Factor-1α in Renal Cell Carcinoma Departments of Surgical and Perioperative Sciences, Urology and Andrology; Radiation Sciences, Oncology; Medical Biosciences, Pathology; and Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden Background: Renal cell carcinoma (RCC) accounts for approximately 2-3% of all human cancers. A distinguished feature of RCC is vascularisation and among the three dominating RCC types conventional RCC (cRCC) generally is more vascularised than papillary RCC (pRCC) and chromophobe RCC (chRCC). Angiogenesis is a critical step in tumour progression controlled by a balance involving molecules that have positive and negative regulatory activity. A balance distorted by metabolic stress such as hypoxia, acidosis, and inflammation. Hypoxia-Inducible Factor 1α (HIF-1α) is a key transcription factor in angiogenesis and tumour progression, targeting more than a 100 genes involved in vascular growth and regulation, iron metabolism and erythropoesis, collagen matrix formation, regulation of extracellular pH, glucose uptake and metabolism, proliferation, apoptosis, differentiation, and cell viability. Methods: Tumour tissue and corresponding kidney cortex from nephrectomised RCC patients was used in order to characterize HIF-1α expression and one of its target genes, Glucose Transporter 1 (GLUT-1). All tumour samples were thoroughly described regarding tumour type, TNM stage, nuclear grade, tumour size, vein invasion, and patient survival. Utilizing RT-PCR, Westen Blot and Tissue micro array (TMA) we studied HIF-1α mRNA and protein expression as well as GLUT-1 protein expression, correlating them to each other and clinicopathological parameters. Results: Using Western Blot, HIF-1α protein expression differed significantly between the different RCC types and kidney cortex. In cRCC, high expression of HIF-1α was an independent prognostic factor for favourable prognosis. TMA is a useful method to analyze HIF-1α protein expression in RCC. HIF-1α levels were significantly lower in locally aggressive cRCC and patients with high levels of HIF-1 tended to have a better prognosis. GLUT-1 levels were higher in cRCC than in other RCC types and for cRCC a correlation to HIF-1α was seen. HIF-1α mRNA levels were significantly lower in cRCC compared to other RCC types and kidney cortex. An inverse correlation between HIF-1α protein expression and mRNA levels was observed. Summary: These results demonstrate a discrepancy between RCC types, highlighting the need to separately evaluate biological events in different RCC types. Overexpression of HIF-1α protein is not necessarily all bad and translational regulation appears more critical than anticipated. Further studies are encouraged to clarify angiogenic pathways in RCC.
|
9 |
An?lise comparativa da imunoexpress?o de GLUT-1, GLUT-3 e M-CSF em les?o perif?rica e central de c?lulas gigantesVasconcelos, Rodrigo Gadelha 18 December 2014 (has links)
Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2016-02-01T21:57:42Z
No. of bitstreams: 1
RodrigoGadelhaVasconcelos_TESE.pdf: 1777603 bytes, checksum: 142978c0b438c9eba25a0468ff97275f (MD5) / Approved for entry into archive by Elisangela Moura (lilaalves@gmail.com) on 2016-03-07T23:32:33Z (GMT) No. of bitstreams: 1
RodrigoGadelhaVasconcelos_TESE.pdf: 1777603 bytes, checksum: 142978c0b438c9eba25a0468ff97275f (MD5) / Made available in DSpace on 2016-03-07T23:32:33Z (GMT). No. of bitstreams: 1
RodrigoGadelhaVasconcelos_TESE.pdf: 1777603 bytes, checksum: 142978c0b438c9eba25a0468ff97275f (MD5)
Previous issue date: 2014-12-18 / A les?o perif?rica de c?lulas gigantes (LPCG) e a les?o central de c?lulas gigantes (LCCG) s?o les?es histologicamente semelhantes que acometem a regi?o de cabe?a e pesco?o. O estudo teve a finalidade de analisar a express?o imuno-histoqu?mica atrav?s dos marcadores GLUT-1, GLUT-3 e M-CSF em uma s?rie de casos de les?o perif?rica e central de c?lulas gigantes, na tentativa de estabelecer poss?veis associa??es e correla??es entre a express?o destas prote?nas nessas les?es, buscando uma melhor compreens?o do diferente comportamento biol?gico dessas entidades patol?gicas. A amostra foi constitu?da por 20 esp?cimes teciduais emblocados em parafina de LPCG, 20 de LCCG n?o agressivo e 20 de LCCG agressivo, oriundos do Servi?o de Anatomia Patol?gica da Disciplina de Patologia Oral do Departamento de Odontologia da UFRN. Em rela??o ao GLUT-1, verificou-se uma diferen?a estatisticamente significante (p< 0,05) na quantidade de c?lulas mononucleares imunomarcadas entre a les?o perif?rica (LP) e a les?o central n?o agressiva (LCNA) e entre a LP e a les?o central agressiva (LCA). Em rela??o ? intensidade da marca??o tamb?m foi verificado uma diferen?a estatisticamente significante tanto para as c?lulas mononucleares quanto para as c?lulas gigantes entre LP e LCNA e entre LP e LCA, nas c?lulas gigantes tamb?m ocorreu uma diferen?a estatisticamente significante entre a LCNA e a LCA. Em rela??o ao GLUT-3, foi encontrada uma diferen?a estatisticamente significante entre LP e LCA e entre LCNA e LCA na quantidade de c?lulas mononucleares imunomarcadas. No que concerne ? intensidade de marca??o para a referida prote?na foi verificado uma diferen?a estatisticamente significante nas c?lulas gigantes entre LP e LCA. Para o M-CSF foi observado apenas uma diferen?a estatisticamente significante na intensidade de marca??o nas c?lulas mononucleares entre LP e LCNA e entre LP e LCA. Com base nestes resultados, pode-se concluir a participa??o do GLUT-1, GLUT-3 e do M-CSF na patog?nese das les?es estudadas. Os transportadores de glicose estariam envolvidos no fornecimento de energia, para o metabolismo energ?tico das c?lulas e a prote?na osteoclastog?nica estaria envolvida no mecanismo de reabsor??o ?ssea encontrada nessas les?es. / The
peripheral
giant cell lesion
(
PG
CL
)
and
the
central
giant cell lesion
(
CGC
L)
are
lesions
histologically
similar
affecting the
head and neck
region
.
The study
aimed to
analyze the
immunohistochemical expression
of
markers GLUT
-
1
,
GLUT
-
3
and
M
-
CSF
in a series of
cases of
PGCL
and
CGCL
,
in trying to understand
the different
biological
behavior
of these
pathologies
.
The
sample consisted of
20
tissue
specimens
of
PGCL 20
central lesion
of
not
aggressive
giant cell
(
CLNAGC)
and 20
central lesi
on
of aggressive
giant cell
(
CLAGC),
coming from the
Pathology Unit
of
Oral Pathology
of
the Department of
Dentistry
of UFRN
.
W
as performed the s
emi
-
quantitative
and
qualitative analysis of
immunohistochemical expression
of the markers in
giant cells
and
m
ononuclear cells
.
In relation to the
GLUT
-
1, it was found
a statistically
significant
difference (p
<
0.05)
in the number of
mononuclear
cells
immunomarked
between the
PGCL
and
the
CLNAGC
and between
the
PGCL
and
CLAGC
.
Regarding the
intensity
of
staining w
as
also observed
a statistically
significant difference
both
at the
mononuclear cells
as in
giant cells
between
PL
and
CLNAGC
and between
PGCL
and
CLAGC
,
at the
giant cells
there was also a
statistically
significant difference
between
the
CLNAGC
and
CLAGC
.
In relation to
GLUT
-
3
,
was found
a statistically
significant
difference
between
PGCL
and
CLAGC
and
between
CLAGC
and
CLNAGC
in
amount
of
mononuclear cells
immunomarked
.
Regarding the intensity of labeling for such
protein was found a statistically
signifi
cant difference at
the giant cells between PL and
CLAGC
.
To
the
M
-
CSF was observed only a statistically
significant difference in
the
intensity
of labeling at
the
mononuclear cells between
PGCL
and
CLNAGC
and
between
PGCL
and
CLAGC
.
Based on these results,
we can conclude the participation
of GLUT
-
1, GLUT
-
3 and M
-
CSF in the pathogenesis of the lesions studied.
The bigger
immunostaining of these proteins in mononuclear cells show that these cells
perform
a
higher metabolic activity and osteoclastogenic, espe
cially in
CLAGC
. It was found that
the mononuclear cells were more related to the pathogenesis of the studied
lesions
than
properly
the giant
s
cell
s.
|
10 |
Estudo imuno-histoqu?mico da express?o da GLUT-1 e mensura??o do ?ndice angiog?nico (CD34) em adenomas pleom?rficos, carcinomas aden?ides c?sticos e carcinomas mucoepiderm?ides de gl?ndulas salivaresOliveira, Lucileide Castro de 27 June 2012 (has links)
Made available in DSpace on 2014-12-17T15:32:22Z (GMT). No. of bitstreams: 1
LucileideCO_DISSERT.pdf: 2248988 bytes, checksum: f9aafad24354c13fb349a052f5b90d8e (MD5)
Previous issue date: 2012-06-27 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / The expression of glucose transporter protein 1 (GLUT-1), as well the angiogenesis has been associated to clinical behavior and aggressiveness in tumors of various origin. It is believed that the expression of this protein denotes metabolic demand of the tumor cells and, thus its influence upon the formation of new blood vessels. Pleomorphic adenoma (PA) and the adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC) represent, respectively, the most commom benign and malignant tumors of salivary glands. The aim of this study was to analyze and compare the immunohistochemical expression of GLUT-1 and its correlation with angiogenesis in cases of PAs, ACCs and MECs considering their histological grades. The sample consisted of 20 PAs, 20 ACCs and 10 MECs. The cases were analyzed and classified according to their histological grades. The expression of GLUT-1 was evaluated in the parenchyma lesions, establishing the percentage of immunopositive cells, according to the following scores: 0 (no cell immunomarked), 1 (up to 25% of tumor cells immunostained), 2 (25 - 50% of tumor cells immunostained) and 3 (more than 50% of tumor cells immunostained). The angiogenic index was analyzed by counting the microvessels immunostained by anti-CD34 antibody, in 5 fields (200X). The analysis of the expression of GLUT-1 in tumor parenchyma showed statistically significant differences between benign and malignant groups (p = 0.022). The average number of microvessels in PAs was 40.4, 21.2 in ACCs and 66.5 in MECs, with significant differences between groups (p <0.001). When compared to the expression of GLUT-1 and angiogenic index as a whole, there was no significant correlation between the number of microvessels and the expression of GLUT-1 (r = 0.211, p = 0.141). In conclusion, the results of this study suggest not only that differences in biological behavior between PAs, ACCs and MECs may be associated to the expression of GLUT-1, but also that benign and malignant salivary gland present differences in the average number of microvessels, with higher levels considered more aggressive tumors. Furthermore, the number of newly formed microvessels can be independent of the metabolic demand of the tumor cells / A express?o da prote?na transportadora de glicose tipo 1 (GLUT-1), bem como a angiog?nese, t?m sido relacionadas ao comportamento cl?nico e agressividade em neoplasias de origem diversas. Acredita-se que a express?o desta prote?na denote a demanda metab?lica das c?lulas tumorais e, assim, a sua influ?ncia na forma??o de novos vasos sanguineos. O adenoma pleom?rfico (AP) e o carcinoma adenoide c?stico (CAC) e carcinoma mucoepiderm?ide (CME) representam, respectivamente, a neoplasia benigna e as malignas mais frequentes das gl?ndulas salivares. O prop?sito deste estudo foi comparar a express?o imuno-histoqu?mica da GLUT-1, bem como correlacionar com a angiog?nese em casos de APs, CACs e CMEs levando em considera??o suas grada??es histol?gicas. A amostra foi composta por 20 APs, 20 CACs e 10 CMEs os quais foram classificados de acordo com os graus histol?gicos apresentados. A express?o da GLUT-1 foi avaliada no par?nquima das les?es, estabelecendo-se o percentual de c?lulas imunopositivas, de acordo com os escores: 0 (nenhuma c?lula imunomarcada), 1 (at? 25% das c?lulas tumorais imunomarcadas), 2 (de 25-50% das c?lulas tumorais imunomarcadas) e 3 (mais de 50% das c?lulas tumorais imunomarcadas). O ?ndice angiog?nico foi analisado por meio da contagem de microvasos imunomarcados pelo anticorpo anti-CD34, em 5 campos (200x). A an?lise da express?o da GLUT-1 revelou diferen?as estatisticamente significativas entre os grupos benignos e malignos (p = 0,022). O n?mero m?dio de microvasos foi de 40,4 em APs, 21,2 em CACs e 66,5 em CMEs, com diferen?as significativas entre os grupos (p < 0,001). Quando comparadas a express?o da GLUT-1 com o ?ndice angiog?nico em conjunto, n?o foi evidenciada correla??o significativa entre a quantidade de microvasos e a express?o da GLUT-1 (r = 0,211; p = 0,141). Os resultados do presente estudo sugerem que as diferen?as no comportamento biol?gico entre APs, CACs e CMEs podem estar relacionadas ? express?o da GLUT-1 e que tumores benignos e malignos de gl?ndulas salivares exibem diferen?as no n?mero m?dio de microvasos, com maiores ?ndices nos tumores considerados mais agressivos. Al?m disto, o n?mero de microvasos neoformados pode ser independente da demanda metab?lica das c?lulas tumorais
|
Page generated in 0.0493 seconds